Patent US4289751A successfully refreshed from Google Patents.
US4289751A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Effervescent enteric-coated formulation of soluble form of erythromycin and therapeutic use thereof
Assignee: Merck and Co Inc
•
Filing: 1980-03-17
•
Granted: 1981-09-15
•
Expires: 2000-03-17
Abstract
Abstract Improved delivery and absorption of erythromycin in warm-blooded animals is achieved by administering thereto a non-toxic pharmaceutical effervescent enteric-coated tablet comprising: (a) an antibiotic effective amount of a non-toxic pharmaceutically acceptable soluble form of erythromycin; (b) a non-toxic pharmaceutically acceptable inert diluent; and (c) a non-toxic pharmaceutically acceptable effervescent couple acid and base; and (d) a non-toxic pharmaceutically acceptable enteric coating maintained over the tableted mixture of (a), (b), and (c) above. The subject composition is extremely useful in the treatment of bacterial infections in warm-blooded animals, particularly in the mitigation and treatment of upper and lower respiratory tract, skin and soft tissue infections of mild to moderate severity.
Inventors
- 👤 John J. Windheuser
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 18:30
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K9/00; A61K9/0002; A61K9/0007; A61K9/20; A61K9/28; A61K9/2806; A61K9/2833; A61K9/286; A61K9/2866
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
80 words
A pharmaceutically acceptable effervescent enteric-coated tablet for orally delivering therapeutic levels of erythromycin to a warm-blooded animal, which comprises a tableted admixture of: (a) an antibiotic effective amount of a non-toxic pharmaceutically acceptable salt of erythromycin which is readily soluble in the intestines; (b) a non-toxic pharmaceutically acceptable inert diluent; and (c) a non-toxic pharmaceutically acceptable effervescent couple acid and base; and (d) a non-toxic pharmaceutically acceptable enteric coating maintained over the tableted admixture of (a), (b), and (c) above.
Claim 2
Dependent Claim
80 words
A pharmaceutically acceptable effervescent enteric-coated tablet for orally delivering therapeutic levels of erythromycin to a warm-blooded animal, which comprises a tableted admixture of: (a) an antibiotic effective amount of a non-toxic pharmaceutically acceptable salt of erythromycin which is readily soluble in the intestines; (b) a non-toxic pharmaceutically acceptable inert diluent; and (c) a non-toxic pharmaceutically acceptable effervescent couple acid and base; and (d) a non-toxic pharmaceutically acceptable enteric coating maintained over the tableted admixture of (a), (b), and (c) above.
Claim 3
Dependent Claim
14 words
The tablet of claim 1, wherein said soluble salt of erythromycin is erythromycin lactobionate.
Claim 4
Dependent Claim
14 words
The tablet of claim 1, wherein said soluble salt of erythromycin is erythromycin glucoheptonate.
Claim 5
Dependent Claim
10 words
The tablet of claim 1, wherein said diluent is talc.
Claim 6
Dependent Claim
24 words
The tablet of claim 1, wherein said acid is a member selected from the group consisting of tartaric acid, citric acid, and phthalic acid.
Claim 7
Dependent Claim
11 words
The tablet of claim 1, wherein said base is sodium bicarbonate.
Claim 8
Dependent Claim
24 words
The tablet of claim 1, wherein said enteric coating is a member selected from the group consisting of cellulose acetate phthalate and hydroxypropylmethylcellulose phthalate.
Claim 9
Dependent Claim
23 words
The tablet of claim 7, wherein said hydroxypropylmethylcellulose phthalate is a member selected from the group consisting of hydroxypropylmethylcellulose phthalate-50 and hydroxypropylmethylcellulose phthalate-45.
Claim 10
Dependent Claim
14 words
The tablet of claim 1, further comprising microcrystalline cellulose as a dry binding agent.
Claim 11
Dependent Claim
23 words
A method for inducing therapeutic levels of erythromycin in a warm-blooded animal which comprises administering thereto a tablet as claimed in claim 1.
References Cited (Backward Citations)
US2866735A
Cited
US2798024A
Cited
US2801952A
Cited
US2969352A
Cited
US2830982A
Cited
US2897121A
Cited
US2993833A
Cited
US3131123A
Cited
US3081233A
Cited
US3198787A
Cited
US3531460A
Cited
US3843787A
Cited
BE749864A
Cited
BE754346A
Cited
CA936803A
Cited
US3689645A
Cited
US3878192A
Cited
US3865935A
Cited
US3891755A
Cited
US4013820A
Cited
US3961041A
Cited
US4076804A
Cited
US4147768A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-09-14 | 1985-03-16 | 1985-09-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-09-14 | 1989-03-16 | 1989-09-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-09-14 | 1993-03-16 | 1993-09-15 | $7700.00 | Window Closed / Lapsed |